Oxaviatin (Oxaliplatin)

Oxaliplatin, the active ingredient in Oxaviatin, is a platinum-based chemotherapy agent presented as a 100 mg powder for intravenous infusion use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaviatin as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH USA supplies Oxaviatin as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oxaviatin is a platinum‑based chemotherapy drug used in the treatment of cancers that arise from the gastrointestinal tract and related pathways.

- Colorectal cancer: improves survival by inhibiting tumour cell replication. - Gastric cancer: used in combination regimens to reduce tumour burden. - Pancreatic cancer: part of multi‑drug protocols to control disease progression.

Oxaviatin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects: - Nausea and vomiting: frequent during and after infusion. - Peripheral neuropathy: tingling or numbness in hands and feet. - Diarrhoea: may be mild to moderate. - Fatigue: general tiredness and reduced stamina. - Myelosuppression: lowered blood cell counts. - Elevated liver enzymes: mild increase in hepatic enzymes.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis or infusion‑related hypersensitivity. - Acute pulmonary toxicity: difficulty breathing or reduced oxygenation. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Thrombocytopenia: low platelet count leading to bleeding tendencies. - Renal impairment: reduced kidney function during treatment. - Cardiac arrhythmias: irregular heart rhythms observed in rare cases.

Before initiating Oxaviatin therapy, clinicians should assess patient suitability and monitor for potential complications.

- Renal function: evaluate creatinine clearance before each cycle. - Hepatic function: check liver enzymes and bilirubin levels. - Neuropathy risk: assess baseline peripheral nerve status. - Hematologic status: monitor complete blood count regularly. - Concomitant ototoxic drugs: avoid or adjust dosing when possible. - Store at ambient temperature: keep in original container, protect from moisture and light.

Oxaviatin can interact with several medicines, altering efficacy or safety; careful review of the patient’s medication list is essential.

Major Interactions (Avoid): - Nephrotoxic agents: concurrent use may worsen kidney injury. - Highly protein‑bound drugs: may displace oxaliplatin, increasing free drug levels.

Moderate Interactions (Monitor Closely): - Antiemetics: dose adjustments may be needed to control nausea. - Anticoagulants: monitor coagulation parameters for bleeding risk. - CYP450 inducers: may reduce oxaliplatin exposure. - Radiotherapy: combined use can increase neurotoxicity. - Herbal supplements: potential unknown effects on drug metabolism.